{"id":"rhb-105","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RHB-105 is a combination therapy consisting of rifabutin, an antibiotic, and hyoscyamine, an anticholinergic agent. The mechanism of action is multifaceted, with rifabutin targeting the bacterial component of COVID-19 and hyoscyamine potentially reducing inflammation and modulating the immune response.","oneSentence":"RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:05.419Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT03198507","phase":"PHASE3","title":"ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2017-06-18","conditions":"Helicobacter Pylori Infection, Dyspepsia","enrollment":455},{"nctId":"NCT01980095","phase":"PHASE3","title":"ERADICATE Hp - Treating Helicobacter Pylori With RHB-105","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-11","conditions":"Dyspepsia, Helicobacter Pylori Infection","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amoxicillin, Omeprazole and Rifabutin"],"phase":"phase_3","status":"active","brandName":"RHB-105","genericName":"RHB-105","companyName":"RedHill Biopharma Limited","companyId":"redhill-biopharma-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}